Jeffrey Wolf, MD, director of the Myeloma Program at UCSF Health, discusses the traditional approaches to hematologic cancers, including autologous and allogeneic transplant, and how recent advances in immunotherapy -- antibody-drug conjuagtes (ADCs), bi-specific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR) T cell therapy – are on track to become the standard of care for patients with melanoma.